Ar­row­head, Take­da liv­er drug head­ed to PhI­II de­spite place­bo re­spon­se's dent on stock

Ar­row­head Phar­ma­ceu­ti­cals re­port­ed Mon­day that its Take­da-part­nered pro­gram re­duced liv­er scar­ring and mu­tant pro­tein lev­els in pa­tients with al­pha-1 an­tit­rypsin de­fi­cien­cy, a rare liv­er dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER